Business Wire

Market Research Proves Success of Galderma’s Harmony Programme for Aesthetic Practice

Del

Market research concludes that Galderma’s Harmony Programme for aesthetic Health Care Professionals (HCPs) significantly increases patient satisfaction. Using Harmony resulted in more returning patients and led to an increase in full face treatments. The research results show how Harmony raises both treatment standards and value in aesthetic practices.

The Harmony programme allows HCPs to spend more time with patients, better understand and define their requests, and as a result, better respond to their expressed needs. Through Harmony, 82% of patients request full face treatment as compared to 63% pre-Harmony. 1

Harmony – Proven Consultation Programme for Aesthetic Practitioners
The Harmony Programme is the first of its kind in aesthetic patient management and now the first to show measured success by research. This new market report demonstrates overall patient satisfaction levels increased from 65% to 85% after the implementation of the Harmony Programme. 1

Galderma developed The Harmony Programme as a comprehensive aesthetic consultation tool for structured, stepwise patient management to encourage dialogue between the practitioner and the patient, increasing patient awareness of the multiple needs that can be served with full face treatment options,” explains Ophélie Massaroni, Global Harmony Programme Manager, Galderma.

A High-Quality Consultation Framework to Grow Aesthetic Practices
The Harmony Programme has also enabled practitioners to increase retention from 53% to 73%.1 For Dr. Ravi Jain, Aesthetic Practitioner, Riverbanks Clinic (Harpenden, UK), “Harmony provides the practitioner a consistent high quality consultation framework. The patients are happier, they opt in for more combination treatments, and they refer more friends to us.”

The research demonstrates that with Harmony 51% of patients now receive a combination of facial injectable treatments, compared to 34% without the Harmony approach. 1

According to Ophélie Massaroni, “The Harmony Programme facilitates the development of a cost-effective personalized treatment plan for each patient. This creates value for money, as a satisfied patient will be more likely to continue with other treatments.” The research revealed the average patient spend increased by 48% following assessment with Harmony. 1

Higher Practitioner and Patient Satisfaction with Harmony
Dr. Jain continues, “Harmony provides a framework where we can go over their original consultation, making it easier to schedule future treatments. More importantly, Harmony allows the patient to participate in their own treatment plan.” Satisfaction with Harmony remains high after 12 months of implementation with 14 out of 15 practitioners likely to both recommend the programme and continue using it in their practice. 1

About Galderma
Galderma, Nestlé Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

About Harmony
The Harmony Programme is a patient management programme developed for leading Health Care Practitioners to master patient consultation. Launched in 2014, Harmony was designed in association with an international multidisciplinary panel of experts. It provides a novel stepwise patient assessment and management method including a suite of sophisticated tools for assessment, facial analysis, and treatment plan follow-up.
http://www.restylane.com/Treatments/Treatment-step-by-step/

References:
1. VIPP Market Research by Research Partnership: Pre-Harmony, Post-Harmony 6-months; Post-Harmony 12-months. 2016.

Contact information

For additional information:
Galderma
Mårten Forrest, +46 768 98 1106
Head of PR & Communication
Aesthetic & Corrective Business
marten.forrest@galderma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00Pressemelding

Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are

More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08Pressemelding

The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15Pressemelding

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03Pressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47Pressemelding

SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom